@Article{,
AUTHOR = {Jean-Baptiste Lattouf, Jenny J. Ko, Margot K. Davis, Christian Constance, Geoffrey T. Gotto},
TITLE = {Side effect management algorithms for niraparib/abiraterone acetate in prostate cancer},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {31},
YEAR = {2024},
NUMBER = {5},
PAGES = {11977--11985},
URL = {http://www.techscience.com/CJU/v31n5/59561},
ISSN = {1488-5581},
ABSTRACT = {<b>Introduction:</b> Niraparib, a PARP1/2 inhibitor, is newly
approved in combination with abiraterone acetate (AA)
plus prednisone or prednisolone (niraparib/AA+P) for
the treatment of adult patients with BRCA-mutated,
treatment-naïve metastatic castration resistant prostate
cancer (mCRPC). Detailed guidance beyond the
prescribing information may be helpful in managing
the side effect profile and dosing practicalities of this
combination therapy.<br/>
<b>Materials and methods:</b> A panel of specialists convened to
design management algorithms for four common niraparib/
AA+P treatment-related adverse events (AEs) in mCRPC;
anemia, thrombocytopenia, hypertension, and nausea. The
algorithms build on Health Canada-approved prescribing
information to highlight practical considerations related to monitoring, treatment adjustment, and specialist referral
to support clinical practice.<br/>
<b>Results:</b> The panel’s recommendations were largely
aligned with the niraparib/AA+P product monograph.
Single agent AA+P followed by reintroduction niraparib/
AA+P using the low dose formulation of niraparib/AA
were common strategies for managing higher grade
AE’s. Recommendations for hypertension management
were expanded to include a sequence of anti-hypertensive
medication trials prior to a change in anti-cancer therapy,
where feasible.<br/>
<b>Conclusion:</b> These algorithms are intended to provide
practical assistance to Canadian clinicians managing
the most common AEs encountered with the novel
combination, niraparib/AA+P, for mCRPC.},
DOI = {}
}